← Search

Data · dataset · 2023

Development of Vitiligo in Patients Treated with BRAF/MEK Inhibitors: A Systematic Review

Listed in Teesside University Research Data Repository

BRAF and MEK inhibitors have emerged as key therapies in the treatment of metastatic melanoma through selective inhibition of the mitogen activated protein kinase (MAPK) pathway.

Description

A rare side effect of BRAF and MEK inhibitors is the development of vitiligo. This systematic review aims to summarize the existing literature on new-onset or exacerbations of vitiligo following BRAF, MEK, or BRAF/MEK combination inhibitor therapy.

Links

Where it is published

Catalogue records · 1

Topics

Provenance · 1 source records, 7 field assertions
SourceKeyLast seenRaw
Teesside University Research Data Repositoryoai:data.mendeley.com/gvzfkkjyks.218 h agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0
concepts[field].anzsrc:field:320205mapping · researchdata tees ac ukvocabulary-mapper@1.0.0keywords['Dermatology']
concepts[field].local:field:earth-environmentalmapping · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0
descriptionsource · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0/metadata/dc/description
licensesource · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0/metadata/dc/rights
publication_datesource · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0
titlesource · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0/metadata/dc/title